MTR Genotype

Two people can eat the same diet, take the same B vitamin supplement, and end up with very different blood levels of homocysteine, folate, and B12. A piece of that difference is written into your DNA. MTR (methionine synthase) is the gene that builds one of the central enzymes in this pathway, and small inherited differences in this gene can change how efficiently your body recycles a damaging amino acid called homocysteine back into something useful.

Knowing your MTR genotype gives you a one-time read on an inherited piece of your folate, B12, and homocysteine biology. It does not predict any disease on its own, but it helps explain why your homocysteine or folate may behave the way it does, and it can shape how aggressively you monitor and supplement these nutrients over a lifetime.

What MTR Actually Does

MTR (methionine synthase) is a vitamin B12-dependent enzyme that sits at a crossroads of one-carbon metabolism, the network of reactions that moves single-carbon chemical groups around your cells to support DNA building and repair. It transfers a methyl group from 5-methyltetrahydrofolate to homocysteine, converting it back into methionine, the building block your body uses to make S-adenosylmethionine, the main methyl donor for DNA methylation and hundreds of other reactions. In plain terms, methionine synthase is one of the main recyclers that prevents homocysteine from piling up and keeps your methylation machinery stocked.

The most studied MTR variant is A2756G (also called rs1805087), which results in an aspartate-to-glycine substitution near the cobalamin-binding domain of the enzyme. Carrying the G version of this variant can shift how efficiently the enzyme runs. Research in different populations has linked the G allele to both higher and lower folate and homocysteine depending on the group studied, which is one reason MTR genotype is best interpreted alongside actual blood levels rather than read as a stand-alone risk score.

How an MTR Variant Affects Homocysteine and Folate

In a study of hypertensive Chinese adults, carrying the MTR 2756AG or GG genotype was independently associated with lower serum folate and a higher risk of folate deficiency, with the effect amplified when paired with the more famous MTHFR C677T variant. A separate cross-sectional study of Chinese preschoolers labeled the AG plus GG combination as a risk genotype linked to lower serum folate and worse cognitive scores. In a study of pregnant women, serum folate and the MTHFR C677T plus MTR A2756G genotypes were the main determinants of total homocysteine levels.

Other work points in a different direction. Some earlier observational studies in Western populations suggested that G carriers may have modestly lower homocysteine, while several larger analyses (including the NHLBI Family Heart Study) found no significant association between MTR genotype and fasting homocysteine at all. The likely explanation is that MTR genotype is one input into a system that also depends heavily on actual folate intake, B12 status, alcohol, smoking, and other gene variants. The same letter at the same DNA position can mean different things at different folate intakes.

Cardiovascular and Clot Risk

MTR genotype has been studied as a contributor to vascular risk through its effect on homocysteine, which observational studies have associated with cardiovascular disease, though the causal role remains debated since B-vitamin trials lowering homocysteine have not consistently reduced cardiovascular events. In one analysis of nearly 600 adults, MTR and MTRR variants tracked with homocysteine ranking, and modest elevations in homocysteine were predicted to translate into a small bump in cardiovascular risk. In a study of 326 South Indians, MTR A2756G alone was not a significant risk factor for deep vein thrombosis, but combining MTRR 66GG with MTR AG/GG risk genotypes cumulatively increased risk about 2.38-fold, with the MTRR 66GG genotype alone associated with about 2.74 times the odds of deep vein thrombosis.

The effect of MTR variants on hard cardiovascular endpoints, on their own, is generally modest. The clearer message is that if you carry one or more risk variants in this pathway, your homocysteine number is something worth knowing, watching, and lowering through nutrition and lifestyle, rather than treating MTR genotype as a verdict.

Pregnancy and Neural Tube Risk

Folate, B12, and methionine synthase are central to early embryonic development, and MTR has been studied as a potential modifier of birth-defect risk. A family-based case-control study in a Chinese population found that MTR polymorphisms at rs1770449 and rs1050993 were associated with non-syndromic congenital heart disease risk and modified the relationship between maternal folate intake and these defects. Several meta-analyses of the MTR A2756G variant specifically have not found a consistent association with congenital heart disease, even though the related MTRR A66G variant does show one.

In a prospective Chinese mother and child cohort of 939 women with adequate folate status, maternal MTR A2756G was not associated with preterm birth, low birth weight, or being small for gestational age. The practical takeaway is that good folate status appears to neutralize a meaningful chunk of the genetic effect, which is one reason knowing your genotype before pregnancy can be useful even if the specific variant is not strongly tied to outcomes on its own.

Cancer Associations

Because methylation supports DNA repair, MTR has been studied across multiple cancer types. In a JANUS cohort study of 2,168 case-control pairs, MTR 2756GG was associated with about 35 percent lower odds of colorectal cancer compared with AA (odds ratio 0.65, 95% CI 0.47-0.90), with the strongest effect in cancers of the distal colon and rectum. A meta-analysis of 27 studies, however, found no overall association between MTR A2756G and colorectal adenoma or cancer risk, though gene-environment interactions with heavy smoking (odds ratio about 2.06) and heavy drinking (odds ratio about 2.00) were suggested. Findings across cohorts are not uniform: a Netherlands cohort study reported that 2756GG was associated with increased colorectal cancer risk, which contrasts with the JANUS result.

Across cancer types, a meta-analysis found that 2756GG was associated with a reduced colorectal cancer risk in Europeans (odds ratio about 0.83) but an elevated risk in Asians (odds ratio about 1.33) under the recessive model, a reminder that ancestry matters when interpreting this variant. In esophageal squamous cell carcinoma treated with chemoradiotherapy, the AG and GG genotypes were associated with a longer median survival of 42 months versus 16 months for AA, and with better histopathologic response to treatment. None of these findings make MTR genotype a screening test for cancer, but they do explain why your genotype may matter alongside diet, alcohol use, and treatment choices.

Cognitive Outcomes

Because methionine synthase activity influences methylation in the brain, several studies have looked at MTR variants and cognition. In adults with late-life depression, the MTR 2756AA genotype was associated with roughly 5.8 times the odds of cognitive impairment compared with AG and GG carriers. In childhood acute lymphoblastic leukemia survivors, MTR rs1805087 was suggestively associated with long-term neurocognitive impairment when discovery and replication cohorts were combined (odds ratio about 1.5, 95% CI 1.0-2.3, p=0.04), a signal also supported by earlier work linking the variant to deficits in attentiveness and response speed.

These signals are early and inconsistent across populations. They do not justify changing how you live based on the genotype alone. They do support the broader theme that this part of your one-carbon metabolism is worth paying attention to over decades, especially through reliable folate and B12 intake.

Reconciling Conflicting Findings

Two things can be true at once. In some populations and contexts, the MTR 2756G allele looks protective and is linked to higher folate and lower homocysteine. In others, the same allele is treated as a risk genotype and is associated with lower folate and worse cognitive scores. This is not a contradiction. MTR genotype is not a clean good number or bad number marker. It is one switch in a wider network whose behavior depends on folate and B12 intake, the rest of your folate-pathway genes, alcohol use, smoking, and ancestry. The takeaway is to interpret your genotype next to your actual homocysteine, folate, and B12 levels, not in isolation.

What This Test Measures and What It Does Not

An MTR genotype test reads the DNA letters at a specific spot or set of spots in your MTR gene. The result is a categorical genotype like AA, AG, or GG, and it does not change over your lifetime. The test does not tell you how much methionine synthase enzyme you are making right now, whether your homocysteine is currently elevated, or whether you are folate or B12 deficient. Those questions still require blood tests of homocysteine, folate, vitamin B12, and ideally methylmalonic acid for B12 status.

When Results Can Be Misleading

• Variant panel coverage: the assay only detects the specific variants it is designed to find, usually A2756G (rs1805087) and sometimes a few additional sites. A normal result does not rule out rare variants elsewhere in the MTR gene that a full sequencing test could pick up.
• Ancestry-specific meaning: the clinical implications of MTR variants differ between Asian, European, South Indian, and other populations, so a generic risk interpretation may be wrong for your background.
• Direct-to-consumer versus clinical-grade testing: consumer reports can include MTR variants but vary in confirmation standards. A clinical-grade test from a certified lab is the right reference when treatment decisions might follow.
• Confusing MTR with MTRR or MTHFR: these are three different genes in the same pathway. A normal MTR genotype does not mean your MTHFR or MTRR variants are also normal.

One-Time Test, Lifetime Use

MTR genotype is fixed at conception. You do not need to repeat the test. The value comes from acting on it for decades. If you carry a risk genotype, the companion blood markers that should be tracked over time are homocysteine, serum folate, vitamin B12, and methylmalonic acid. A reasonable cadence for those is a baseline now, a recheck in three to six months if you change your diet or supplement routine, and at least annual monitoring thereafter. If you also carry MTHFR or MTRR variants, that monitoring becomes more important, because gene-gene interactions raise the odds of folate deficiency and elevated homocysteine.

What an Out-of-Pattern Result Should Make You Do

If you discover you carry an MTR risk genotype, the next step is not to retest the gene. It is to map your current state. Order or review homocysteine, serum folate, vitamin B12, and methylmalonic acid together. If homocysteine is elevated despite normal folate and B12, consider testing MTHFR and MTRR as well, since combined variants amplify the effect. If your folate or B12 is low, address intake first and reassess in a few months.

If you are planning a pregnancy, your obstetrician or a genetic counselor should know about your genotype before conception so that folate and B12 status can be optimized. If you have a personal or family history of premature cardiovascular disease, venous thrombosis, or recurrent pregnancy loss, share the result with a cardiologist or hematologist who can decide whether more aggressive workup is warranted. A genetic counselor can help you interpret the result in the context of your ancestry and family history, especially if multiple folate-pathway variants come back together.